“…Synthesis of butorphanol was first reported in 1973 as a product of a program directed towards creation of narcotic antagonists in which potent clinical analgesic activity could be found at doses that did not elicit significant psychotomimetic effects (1). At normal therapeutic doses, butorphanol was concluded to possess analgesic activity with an abuse potential and dependence liability lower than that exhibited by morphine (2,3).…”
Abstract. The opioid analgesic, butorphanol (17-cyclobutylmethyl-3,14-dihydroxymorphinan) tartrate is a prototypical agonist-antagonist opioid analgesic agent whose potential for abuse has been the cause of litigation in the United States. With a published affinity for opioid receptors in vitro of 1:4:25 (µ:δ:κ), the relative contribution of actions at each of these receptors to the in vivo actions of the drug are an issue of active investigation. A body of evidence has been developed which indicates that a substantial selective action of butorphanol on the κ-opioid receptor mediates the development of tolerance to butorphanol and cross-tolerance to other opioid agonists; to the production of dependence upon butorphanol, particularly in the rodent; and to compensatory alterations in brain opioid receptor-effector systems. This perspective will identify the current state of understanding of the effects produced by butorphanol on brain opioid receptors, particularly on the κ-opioid receptor subtype, and on the expression of phosphotyrosyl proteins following chronic treatment with butorphanol.
“…Synthesis of butorphanol was first reported in 1973 as a product of a program directed towards creation of narcotic antagonists in which potent clinical analgesic activity could be found at doses that did not elicit significant psychotomimetic effects (1). At normal therapeutic doses, butorphanol was concluded to possess analgesic activity with an abuse potential and dependence liability lower than that exhibited by morphine (2,3).…”
Abstract. The opioid analgesic, butorphanol (17-cyclobutylmethyl-3,14-dihydroxymorphinan) tartrate is a prototypical agonist-antagonist opioid analgesic agent whose potential for abuse has been the cause of litigation in the United States. With a published affinity for opioid receptors in vitro of 1:4:25 (µ:δ:κ), the relative contribution of actions at each of these receptors to the in vivo actions of the drug are an issue of active investigation. A body of evidence has been developed which indicates that a substantial selective action of butorphanol on the κ-opioid receptor mediates the development of tolerance to butorphanol and cross-tolerance to other opioid agonists; to the production of dependence upon butorphanol, particularly in the rodent; and to compensatory alterations in brain opioid receptor-effector systems. This perspective will identify the current state of understanding of the effects produced by butorphanol on brain opioid receptors, particularly on the κ-opioid receptor subtype, and on the expression of phosphotyrosyl proteins following chronic treatment with butorphanol.
“…This was reduced with lithium aluminum hydride to the 10P-thiohasubanan 7, which in turn was hydrogenolized with Raney nickel to afford 8. The reaction of 8 with methyl iodide gave quaternary salt 9 and treatment of this with potassium hydroxide in boiling 1-butanol (Hofmann elimination conditions) afforded aminohexahydrophenanthrene 10, which was identical to the sample obtained by reductive methylation (Raney Ni, H,, CH,O) of the aminohexahydrophenanthrene 11 (1 For personal use only.…”
Section: Resultsmentioning
confidence: 75%
“…The reaction of 3-methoxy-~~~'~-morphinan (1) with phenyl isothiocyanate afforded the starting material, thioamidomorphinan 1. Treatment of 1 with concentrated sulfuric acid a t room temperature afforded a mixture of thioureidohasubanan 2 (68%) and thiazinohasubanan 3 (8'3).…”
The acid-catalyzed rearrangement of 3-methoxy-17-(N-phenylthioamido)-Δ8,14-morphinan (1) to 3-methoxy-17-(N-phenylthioamido)- Δ9,10-hasubanan (2), and acid-catalyzed cyclization of 2 to thiazinohasubanan (3) are described. Both transformations are discussed in terms of intramolecular vs. intermolecular hydride (proton) transfers. The reduction of 3 afforded 3-methoxy-10β-thiohasubanan (4), which was further hydrogenolized to 3-methoxy-hasubanan (5).
“…Later Generally speaking, 2,2-tetramethylene-]-tetra-Papers will describe the cyclization a n d related lone 2 (R' = H or 0 C H 3 ) can react with chemistry of some of these 4-type systems (10). Reformatsky (I), Grignard (I), Wittig or Carey's A ~0mmunication concerning the application of reagents to give adducts that are especially prone the above described approach has been published to suffer Wagner-Meerwein arrangements so as recently (9). to yield 4a-substituted-1,2,3,4,4a,9-hexahydrophenanthrenes (4) and/or the isomeric 2,3,4,4a,-…”
The synthesis of 1-aminoalkyl-1-hydroxy-2,2-tetramethylene-1,2,3,4-tetrahydronaphthalenes and their Wagner–Meerwein rearrangements into 4a-aminoalkyl-1,2,3,4,4a,9-hexahydrophen-anthrenes are described.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.